These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

57 related articles for article (PubMed ID: 23258564)

  • 1. Stability of the recombinant anti‑erbB2 scFv‑Fc‑interleukin‑2 fusion protein and its inhibition of HER2‑overexpressing tumor cells.
    Du YJ; Lin ZM; Zhao YH; Feng XP; Wang CQ; Wang G; Wang CD; Shi W; Zuo JP; Li F; Wang CZ
    Int J Oncol; 2013 Feb; 42(2):507-16. PubMed ID: 23258564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficient growth inhibition of ErbB2-overexpressing tumor cells by anti-ErbB2 ScFv-Fc-IL-2 fusion protein in vitro and in vivo.
    Shi M; Zhang L; Gu HT; Jiang FQ; Qian L; Yu M; Chen GJ; Luo Q; Shen BF; Guo N
    Acta Pharmacol Sin; 2007 Oct; 28(10):1611-20. PubMed ID: 17883948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of non-small cell lung cancer cell proliferation and tumor growth by vector-based small interfering RNAs targeting HER2/neu.
    Ren XL; Xu YM; Bao W; Fu HJ; Wu CG; Zhao Y; Li ZK; Zhang J; Li SQ; Chen WQ; Wang T; Zhang R; Zhang LH; Qian GS; Chen SY; Jia LT; Yang AG
    Cancer Lett; 2009 Aug; 281(2):134-43. PubMed ID: 19339104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delivery of NKG2D ligand using an anti-HER2 antibody-NKG2D ligand fusion protein results in an enhanced innate and adaptive antitumor response.
    Cho HM; Rosenblatt JD; Tolba K; Shin SJ; Shin DS; Calfa C; Zhang Y; Shin SU
    Cancer Res; 2010 Dec; 70(24):10121-30. PubMed ID: 21159634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A bispecific enediyne-energized fusion protein containing ligand-based and antibody-based oligopeptides against epidermal growth factor receptor and human epidermal growth factor receptor 2 shows potent antitumor activity.
    Guo XF; Zhu XF; Shang Y; Zhang SH; Zhen YS
    Clin Cancer Res; 2010 Apr; 16(7):2085-94. PubMed ID: 20332319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel design of targeted endocrine and cytokine therapy for breast cancer.
    Zhang G; Li W; Holle L; Chen N; Chen WY
    Clin Cancer Res; 2002 Apr; 8(4):1196-205. PubMed ID: 11948133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted delivery of tumor antigens to activated dendritic cells via CD11c molecules induces potent antitumor immunity in mice.
    Wei H; Wang S; Zhang D; Hou S; Qian W; Li B; Guo H; Kou G; He J; Wang H; Guo Y
    Clin Cancer Res; 2009 Jul; 15(14):4612-21. PubMed ID: 19584156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced inhibition of murine tumor and human breast tumor xenografts using targeted delivery of an antibody-endostatin fusion protein.
    Cho HM; Rosenblatt JD; Kang YS; Iruela-Arispe ML; Morrison SL; Penichet ML; Kwon YG; Kim TW; Webster KA; Nechustan H; Shin SU
    Mol Cancer Ther; 2005 Jun; 4(6):956-67. PubMed ID: 15956253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I.
    Sachdev D; Li SL; Hartell JS; Fujita-Yamaguchi Y; Miller JS; Yee D
    Cancer Res; 2003 Feb; 63(3):627-35. PubMed ID: 12566306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Houttuyninum, an active constituent of Chinese herbal medicine, inhibits phosphorylation of HER2/neu receptor tyrosine kinase and the tumor growth of HER2/neu-overexpressing cancer cells.
    Zhou NN; Tang J; Chen WD; Feng GK; Xie BF; Liu ZC; Yang D; Zhu XF
    Life Sci; 2012 May; 90(19-20):770-5. PubMed ID: 22525372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A recombinant IgG3-(IL-2) fusion protein for the treatment of human HER2/neu expressing tumors.
    Penichet ML; Dela Cruz JS; Shin SU; Morrison SL
    Hum Antibodies; 2001; 10(1):43-9. PubMed ID: 11455061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bispecific anti-HER2 and CD16 single-chain antibody production prolongs the use of stem cell-like cell transplantation against HER2-overexpressing cancer.
    Kasuya K; Shimazu M; Suzuki M; Itoi T; Aoki T; Tsuchida A
    Int J Mol Med; 2010 Feb; 25(2):209-15. PubMed ID: 20043129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Construction and characterization of novel, recombinant immunotoxins targeting the Her2/neu oncogene product: in vitro and in vivo studies.
    Cao Y; Marks JD; Marks JW; Cheung LH; Kim S; Rosenblum MG
    Cancer Res; 2009 Dec; 69(23):8987-95. PubMed ID: 19934334
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined radioimmunotherapy and chemotherapy of breast tumors with Y-90-labeled anti-Her2 and anti-CEA antibodies with taxol.
    Crow DM; Williams L; Colcher D; Wong JY; Raubitschek A; Shively JE
    Bioconjug Chem; 2005; 16(5):1117-25. PubMed ID: 16173788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers.
    Pegram M; Hsu S; Lewis G; Pietras R; Beryt M; Sliwkowski M; Coombs D; Baly D; Kabbinavar F; Slamon D
    Oncogene; 1999 Apr; 18(13):2241-51. PubMed ID: 10327070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Targeted detecting HER2 expression with recombinant anti HER2 ScFv-GFP fusion antibody].
    Gao G; Chen C; Yang Y; Yang H; Wang J; Zheng Y; Huang Q; Hu X
    Sheng Wu Gong Cheng Xue Bao; 2012 Aug; 28(8):1002-14. PubMed ID: 23185900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Controlled growth of Chinese hamster ovary cells and high expression of antibody-IL-2 fusion proteins by temperature manipulation.
    Shi M; Xie Z; Yu M; Shen B; Guo N
    Biotechnol Lett; 2005 Dec; 27(23-24):1879-84. PubMed ID: 16328984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
    Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
    Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells.
    Kurokawa H; Lenferink AE; Simpson JF; Pisacane PI; Sliwkowski MX; Forbes JT; Arteaga CL
    Cancer Res; 2000 Oct; 60(20):5887-94. PubMed ID: 11059787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-Her2 single-chain antibody mediated DNMTs-siRNA delivery for targeted breast cancer therapy.
    Dou S; Yao YD; Yang XZ; Sun TM; Mao CQ; Song EW; Wang J
    J Control Release; 2012 Aug; 161(3):875-83. PubMed ID: 22762887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.